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Abstract (150 word limit) 
Excessive fecal bile acid (BA) loss causes symptoms in a large proportion of people diagnosed with 
irritable bowel syndrome with diarrhea, a common functional bowel disorder. This bile acid diarrhea 
(BAD) results from increased hepatic synthesis of BAs, with impaired negative feedback regulation by 
the ileal hormone fibroblast growth factor 19 (FGF19).  In this issue of the JCI, Zhao et al. 
investigated BA metabolism, including fecal BAs, serum BAs and FGF19, in patients and controls.  
They identified associations with fecal bacterial BA metabolism and specific microbiota, especially 
Clostridium scindens. These findings have been tested in a mouse model using microbiota 
transplants and antibiotic treatment. This group of organisms has potential as a biomarker for BAD 
and to be a target for therapy. 
  
Pathophysiology of the functional bowel disorders  
Bile acids (BAs) are increasingly recognized as major factors in the pathophysiology of the 
functional bowel disorders with diarrhea (1,2). Recent guidelines recommend investigation of 
patients with chronic diarrhea to detect the presence of BA diarrhea (BAD) (3,4).  Such patients may 
meet the diagnostic criteria for irritable bowel syndrome with predominant diarrhea (IBS-D) or 
functional diarrhea (FD), depending on how they report abdominal pain (1), but they all experience 
frequent, soft or liquid stools, with urgency and often fecal incontinence, with a response to BA 
sequestrants (5).  Diagnostic delay is common, as the recognition of BAD by physicians is poor, and 
there is limited availability of diagnostic tests, such as the nuclear medicine 75Selenohomocholic acid 
taurine (SeHCAT) test (4,6). SeHCAT is unavailable in the U.S.A., which has led to the development of 
alternative blood or fecal tests (7). The frequency of BAD is estimated at 28% in IBS-D or FD, giving a 
population prevalence of 1% (8-10). 
The precise causes of this idiopathic, primary BAD (PBAD) have largely been unclear. BA are 
mostly reabsorbed in the ileum and undergo an enterohepatic circulation. BA malabsorption, which 
is clearly present in ileal Crohn’s disease or resection, is usually not found in PBAD. An alternative 
cause for the excess fecal BA loss is increased hepatic BA synthesis (6,11). BAs are synthesized from 
cholesterol by the enzyme, cholesterol 7α-hydroxylase, (CYP7A1). Raised levels of the BA 
intermediate 7α-OH-4-cholesten-3-one (C4) demonstrate the increased activity of the classical 
synthesis pathway, where CYP7A1 is rate-limiting. This enzyme is regulated via negative feedback by 
the ileal hormone fibroblast growth factor 19 (FGF19). Serum FGF19 levels are usually low in PBAD, 
and are inversely correlated with C4 (12).  In ileal tissue, BA and other agonists bind to the receptor 
known as the farnesoid X receptor (FXR), to stimulate FGF19 transcription (13).  In PBAD, there is 
evidence for impaired FGF19 production from the ileum (14). Further, PBAD is associated with 
certain polymorphisms in genes (FGFR4 and KLB) that affect the hepatic response to FGF19 (15). 
 
A possible cause of primary bile acid diarrhea  
 In this issue of the JCI, Zhao et al. investigated the relevance of the BA-FXR signalling 
pathway and the effects of microbial metabolism of BA in relation to the possible cause of PBAD 
(16). Starting with an unselected population of 345 Chinese adults who met Rome IV criteria for IBS-
D (1), the authors identified around 25% of these with excess total fecal BA (called the BA+IBS-D 
group by Zhao et al.). This figure is a similar proportion to the IBS-D patients reported elsewhere 
with PBAD (8-10). Importantly, the authors showed that the BA-positive group, when compared to 
the BA-negative group, also showed raised serum C4 and total BA levels, with lower FGF19. Total 
fecal BAs were associated with increased symptom severity, increased BA synthesis and impaired 
FGF19 feedback, making the Zhao et al. study patients representative of those studied previously 
(16). 
BA profile differences in serum and fecal samples of the BA-positive group suggest that there 
are differences in the BA-transforming microbiota in PBAD. In the serum, BAs conjugated with 
glycine or taurine and the free unconjugated liver-derived (primary) BAs, cholic acid (CA), and 
chenodeoxycholic acid (CDCA) predominated. CDCA and glycochenodeoxycholic acid (GCDCA) were 
raised, and the secondary BA, ursodeoxycholic acid (UDCA) and its conjugated form, 
glycoursodeoxycholic acid (GUDCA) were also particularly higher in the BA-positive group.  Similarly, 
in feces, increases in the total of most BAs, and the proportions of CA, CDCA, UDCA and 7-
ketodeoxycholic acid (7-KDCA) were found. Relevantly, identifying raised levels of unconjugated 
primary BA (CA and CDCA) in fecal samples has been proposed as a novel diagnostic method to 
identify PBAD (7).   
Intestinal bacteria possess specialized BA modifying enzymes, and consequently are integral 
to BA metabolism. Deconjugation, removing glycine or taurine, by choloylglycine hydrolase genes 
(cgh, also known as bile salt hydrolases), and 7-dehydroxylation/dehydrogenation by bais genes (7-
dehydroxylases) and hdhA (7α-hydroxysteroid dehydrogenase, 7-HSDH) are key to the production of 
the secondary, modified BAs. Using shotgun metagenomics and DNA extracted from the feces of the 
study group, Zhao et al. found reduced Bacteroidetes, with decreased abundances of Alistipes and 
Bacteroides, which express cgh, contributing to the reduced activity, and less bile acid deconjugation 
in the BA-positive patients (the BA+IBS-D group). This group had an increase in their microbiota in 
Firmicutes, including Clostridia and especially Clostridium scindens, with significantly higher 
abundance of 7-dehydroxylation/dehydrogenation genes.  The abundance of C. scindens was 
positively associated with total fecal BA and serum C4, and, notably, was inversely related to serum 
FGF19 levels (16). 
A key step for the investigators involved recapitulating these findings in mice. Human fecal 
microbiota was transplanted into pseudo germ-free mice, and after one week, those that had 
received feces from the group of BA-positive patients had cecal microbiota with decreased 
deconjugating ability, increased 7-HSDH and 7α–dehydroxylating levels. They also had 
pathophysiologic differences, increased fecal water and BA, increased serum C4 and hepatic BA-
synthesis enzyme activity and decreased ileal FGF15 (the mouse homolog of human FGF19). No 
differences in ileal BA transporters or hepatic receptors was identified. The Firmicutes/Bacteroidetes 
ratio was higher, and increases in Clostridium cluster XIVa and C. scindens were found (16). 
Next, modifications to the microbiota of conventional mice were made. The researchers 
either directly administered C. scindens into the stomachs or, alternatively, treated the mice with 
vancomycin, an antibiotic that inhibits Clostridium species. Levels of 7-HSDH and 7α–dehydroxylating 
activity changed in keeping with the previous findings, as did BA and gene expression. C. scindens 
enhanced BA synthesis and excretion, reducing ileal FGF15 at both transcript and protein levels.  
Conversely, vancomycin increased ileal Fgf15 and inhibited hepatic Cyp7a1 gene expression (16). 
Cell-line studies were performed to add to these findings. In the hepatocyte L-02 cell-line, 
vancomycin or C. scindens failed to produce direct effects on CYP7A1 expression. In NCI-H716 cells, 
which have an enterocyte-like phenotype, CDCA stimulated FGF19 expression, as previously 
demonstrated in similar cells (17), confirming findings with human ileal tissue that FXR agonists 
regulate this gene potently (13).  Further, coincubating the cells with other BAs, including GUDCA, 
GCDCA, GCA, UDCA or 7-KDCA, inhibited the CDCA stimulated FGF19 (16).. 
Other research has suggested that certain modified, secondary BA can have actions as FXR 
antagonists. For example, tauro-β-muricholic acid was shown to act as an antagonist (18), but 
humans, unlike mice, have very low levels of this BA. In the Zhao et al. study, the related metabolite, 
ω-muricholic acid, was detected at higher levels in feces of BA-positive patients. GUDCA also has FXR 
antagonist effects, and is increased by metformin, which decreases a specific Bacteroides and can 
also cause BAD (19,20).  
Clinical implications 
The findings in Zhao et al. are significant and important, advancing our understanding of the 
role of the gut microbiota and BAs in IBS-D. They will need to be confirmed in other defined groups 
of PBAD, such as those diagnosed by reduced SeHCAT retention, blood tests or by raised fecal total 
or primary BA (6,7). They add to previous PBAD mechanistic studies, where overproduction of BAs 
with raised C4, due to impaired FGF19-related negative feedback, are central (6).  Reduced 
deconjugation of BAs gives higher levels of fecal primary BAs (7), but increased 7-
dehydroxylation/dehydrogenation produces secondary BAs, which can be reabsorbed and then 
conjugated.  If these conjugated secondary BAs, like GUDCA, inhibit FXR, their increase could explain 
the reduced ileal FGF19 production. 
The microbial and enzymatic changes associated with IBS-D and outlined by Zhao et al. need 
considering alongside other possible factors (Figure)(16). For example, lower basal and stimulated 
FGF19 transcript levels have been shown in patient ileal mucosa explant cultures, implying an 
inherent defect can predispose individuals to PBAD (14). There is also evidence that Diet1 protein 
regulates FGF19 protein secretion, and that Diet1 genetic variants associate with PBAD (21).  
Further, variants in FGF19 hepatic response genes (FGFR4 and KLB) may also contribute to PBAD 
(15). 
We now have a target group of organisms, which might be considered to be a biomarker for 
BAD.  This may allow the development of a quick molecular test to detect levels of C. scindens 
relative to other bacteria in fecal samples. Moreover, since the human population’s gut microbiota 
sits along a continuum with different ratios of Firmicutes/Bacteroidetes, it also raises the possibility 
that we could be able to predict which individuals, enriched with Firmicutes, who could have a 
higher prevalence of PBAD and/or IBS-D with high levels of BA. Is this population of Firmicutes, and 
specifically the enhanced Clostridia and C. scindens, maintained by the higher BA levels or due to 
other unknown factors? There is still much work to be done to prove the relevance of these findings 
and the exact relationships of these microbiota with BA metabolism and PBAD in individuals with 
IBS-D.  Nevertheless, antibiotic treatment trials, with vancomycin or others targeting Clostridia 
rather than Bacteroidetes, may be beneficial in PBAD and should be one of the many outcomes of 
this notable study.   
 
Figure legend 
Factors contributing to BA diarrhea  
The key physiological steps in BA metabolism (black) produce or interact with specific factors (blue) 
that can contribute to the pathophysiology of altered BA metabolism and thus result in chronic 
diarrhea. Bacterial species influence various BA proportions (varying arrow width) and influence 
FGF19 signaling (blue arrow) See text for abbreviations. 
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